TGFB1 and Marfan syndrome: The angiotensin receptor blocker (ARB) losartan (which down-regulates TGFβ signaling) rescued the aortic phenotype in a mouse model of Marfan syndrome,17 suggesting that targeted manipulation of TGFβ or its downstream pathways and regulators could prove to be productive strategies for the prevention of aortic disease in Marfan syndrome in patients.18-29